



(86) Date de dépôt PCT/PCT Filing Date: 2006/01/11
(87) Date publication PCT/PCT Publication Date: 2006/07/20
(45) Date de délivrance/Issue Date: 2013/10/01
(85) Entrée phase nationale/National Entry: 2007/07/12
(86) N° demande PCT/PCT Application No.: EP 2006/000198
(87) N° publication PCT/PCT Publication No.: 2006/074918
(30) Priorité/Priority: 2005/01/12 (DE10 2005 001 479.8)

(51) Cl.Int./Int.Cl. *A61K 31/525* (2006.01),
A61K 31/4415 (2006.01), *A61K 31/714* (2006.01),
A61P 7/02 (2006.01), *A61P 9/10* (2006.01)
(72) Inventeur/Inventor:
GOERNE, MARTIN, DE
(73) Propriétaire/Owner:
PHRONTIER S.A.R.L., FR
(74) Agent: DEETH WILLIAMS WALL LLP

(54) Titre : AGENT CONTENANT DE L'ACIDE FOLIQUE ET DES VITAMINES B6 ET B12 ET UTILISATION DE CET AGENT

(54) Title: AGENTS CONTAINING FOLIC ACID, VITAMIN B6 AND VITAMIN B12, AND THE USE THEREOF

(57) **Abrégé/Abstract:**

The invention relates to agents that contain folic acid, vitamin B6 and vitamin B12, and to the use thereof in hyperhomocysteinemia for controlling homocysteine levels. The agents are mainly suitable for the preventive and acute treatment of vascular diseases, of pregnant women and neurodegenerative diseases and are particularly advantageous in cases where the homocysteine levels to be controlled are found in an individual suffering from renal failure or being treated with immune suppressors. The invention particularly relates to pharmaceutical agents and food supplements comprising a corresponding active ingredient combination and to agents in the form of commercial packages containing corresponding combination preparations or monopreparations for the combined use.



(12) NACH DEM VERTRAG ÜBER DIE INTERNATIONALE ZUSAMMENARBEIT AUF DEM GEBIET DES
PATENTWESENS (PCT) VERÖFFENTLICHTE INTERNATIONALE ANMELDUNG(19) Weltorganisation für geistiges Eigentum
Internationales Büro(43) Internationales Veröffentlichungsdatum
20. Juli 2006 (20.07.2006)

PCT

(10) Internationale Veröffentlichungsnummer
WO 2006/074918 A1

(51) Internationale Patentklassifikation:

A61K 31/525 (2006.01) A61P 9/10 (2006.01)

A61K 31/4415 (2006.01) A61P 7/02 (2006.01)

A61K 31/714 (2006.01)

(21) Internationales Aktenzeichen: PCT/EP2006/000198

(22) Internationales Anmeldedatum:

11. Januar 2006 (11.01.2006)

(25) Einreichungssprache: Deutsch

(26) Veröffentlichungssprache: Deutsch

(30) Angaben zur Priorität:

10 2005 001 479.8 12. Januar 2005 (12.01.2005) DE

(71) Anmelder (für alle Bestimmungsstaaten mit Ausnahme von
US): SYNAVIT GMBH [DE/DE]; Johann-Clanze-Str. 35
A, 81369 München (DE).

(72) Erfinder; und

(75) Erfinder/Anmelder (nur für US): GÖRNE, Martin
[DE/DE]; Am Stein 46, 22337 Hamburg (DE).(74) Anwalt: REITSTÖTTER, KINZEBACH & PARTNER
(GBR); Sternwartstr. 4, 81679 München (DE).(81) Bestimmungsstaaten (soweit nicht anders angegeben, für
jede verfügbare nationale Schutzrechtsart): AE, AG, AL,AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES,
FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE,
KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV,
LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI,
NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG,
SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US,
UZ, VC, VN, YU, ZA, ZM, ZW.(84) Bestimmungsstaaten (soweit nicht anders angegeben, für
jede verfügbare regionale Schutzrechtsart): ARIPO (BW,
GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG,
ZM, ZW), eurasisches (AM, AZ, BY, KG, KZ, MD, RU,
TJ, TM), europäisches (AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC,
NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG,
CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Veröffentlicht:

- mit internationalem Recherchenbericht
- vor Ablauf der für Änderungen der Ansprüche geltenden
Frist; Veröffentlichung wird wiederholt, falls Änderungen
eintreffen

Zur Erklärung der Zweibuchstaben-Codes und der anderen Ab-
kürzungen wird auf die Erklärungen ("Guidance Notes on Co-
des and Abbreviations") am Anfang jeder regulären Ausgabe der
PCT-Gazette verwiesen.

(54) Title: AGENTS CONTAINING FOLIC ACID, VITAMIN B6 AND VITAMIN B12, AND THE USE THEREOF

(54) Bezeichnung: MITTEL, ENTHALTEND FOLSÄURE, VITAMIN B6 UND VITAMIN B12, UND DESSEN VERWEN-
DUNG(57) Abstract: The invention relates to agents that contain folic acid, vitamin B6 and vitamin B12, and to the use thereof in hy-
perhomocysteinemia for controlling homocysteine levels. The agents are mainly suitable for the preventive and acute treatment of
vascular diseases, of pregnant women and neurodegenerative diseases and are particularly advantageous in cases where the homo-
cysteine levels to be controlled are found in an individual suffering from renal failure or being treated with immune suppressors. The
invention particularly relates to pharmaceutical agents and food supplements comprising a corresponding active ingredient combi-
nation and to agents in the form of commercial packages containing corresponding combination preparations or monopreparations
for the combined use.(57) Zusammenfassung: Die vorliegende Erfindung betrifft Mittel, enthaltend Folsäure, Vitamin B6 und Vitamin B12, und deren
Verwendung bei Hyperhomocysteinämie zur Regulation von Homocysteinspiegeln. Die Mittel sind damit vor allem zur vorbeugen-
den und akuten Behandlung von vaskulären Erkrankungen, schwangeren Frauen und neurodegenerativen Er krankungen brauchbar
und bringen besondere Vorteile in solchen Fällen, bei denen die zu regulierenden Homocysteinspiegel bei ei- J_Q nem niereninsuf f
izienten oder immunsuppressiv behandelten Indivi duum auftreten. Beschrieben werden insbesondere pharmazeutische Mittel und
Nahrungsergänzungsmittel mit einer entsprechenden Wirkstoffkombination sowie Mittel in Form von Handelspackungen mit ent-
sprechenden Kombinationspräparaten oder Monopräparaten zur kombinierten Anwendung.

WO 2006/074918 A1

WO 2006/074918

PCT/EP2006/000198

- 1 -

Agents containing folic acid, vitamin B6 and vitamin B12, and the use thereof

5 The present invention relates to compositions comprising folic acid, vitamin B6 and vitamin B12, and to the use thereof for regulating homocysteine levels. The compositions can thus be used in particular for the preventive and acute treatment of vascular disorders.

10 Descriptions are given in particular of pharmaceutical compositions and food supplements with a corresponding active ingredient combination, and compositions in the form of commercial packs with corresponding combination products or single-ingredient products for combined

15 use.

It has recently been disclosed that homocysteine is a risk factor for coronary, peripheral and cerebral vascular disorders. Patients with hereditary

20 hyperhomocysteinemia, an autosomal recessive disorder, have homocysteine plasma levels which are about 10-20 times higher than the normal levels. In children affected by the homozygous form of the disorder, vascular lesions become evident at an early date and

25 represent the main cause of the frequently fatal outcome of the disorder in childhood. Whereas elevated homocysteine levels in the genetically related forms of hyperhomocysteinemia are usually attributable to a deficiency of cystathionine β -synthase and/or a

30 mutation in 5,10-methylenetetrahydrofolate reductase, it is also possible for alterations in folic acid, vitamin B6, vitamin B12 and betaine metabolism to lead to elevated homocysteine levels. Accordingly, acquired types of hyperhomocysteinemia may also occur. For

35 example, renal failure or a deficiency of folic acid, cobalamin and/or pyridoxine or metabolites thereof may lead to elevated homocysteine levels. Especially in elderly people, such a vitamin deficiency, which may be

WO 2006/074918

PCT/EP2006/000198

- 2 -

caused by an inadequate intake or by malabsorption, is regarded as the most frequent cause of acquired hyperhomocysteinemia.

- 5 Vitamin B12 is necessary in order to transfer a 1-carbon unit on folic acid to homocysteine and to convert the latter into methionine. Vitamin B6 is involved in a further metabolic pathway for the degradation of excess homocysteine.

10

It has already been proposed to employ a wide variety of folic acid, vitamin B6 and vitamin B12 containing vitamin products to reduce elevated homocysteine levels.

15

- For example, US 5 932 624 describes a composition which contains 500 µg of folic acid, 25 µg of vitamin B12 and 10 mg of vitamin B6. Depending on the patient's condition, in general 300 to 2000 µg of folic acid, 25
20 to 1000 µg of vitamin B12 and 5 to 20 mg of vitamin B6 should be administered for the homocysteine plasma levels to fall to normal levels.

- The combination indicated in US 6 274 170 of vitamins
25 and aspirin for the treatment of atherosclerotic cardiovascular disorders contains 400 to 1000 µg of folic acid, 3 to 25 mg of vitamin B6 and 5 to 500 µg of vitamin B12.

- 30 A multivitamin and mineral supplement which, besides a number of other vitamins and essential trace elements, contains 800 µg of folic acid, 25 mg of vitamin B6 and 400 µg of vitamin B12 is described in US 6 299 896. This composition is also said to be able to reduce the
35 homocysteine levels.

Daily intake of 180 to 800 µg of folic acid, 1.6 to 4.6 mg of vitamin B6 and 1.5 to 4.0 µg of vitamin B12

WO 2006/074918

PCT/EP2006/000198

- 3 -

together with β -glucan- or glucomannan-containing fibers is recommended in US 6 210 686 in order to improve the composition of serum lipids, to reduce homocysteine levels and to protect lipoproteins from
5 oxidation.

According to US 6 297 224, and US 6 207 651 and US 5 563 126 which are related thereto, vitamin preparations which contain 0.4 mg or 1.0 mg of folic
10 acid together with 25 mg of vitamin B6 and 2.0 mg of vitamin B12 are to be employed for the prevention and treatment of elevated homocysteine, cystathionine, methylmalonic acid or 2-methylcitric acid serum levels.

15 US 6 129 918 describes a garlic-based composition for reducing homocysteine plasma levels. In addition to garlic or garlic extract, this composition may comprise folic acid, vitamin B6 and vitamin B12. The last three active ingredients mentioned are in this case intended
20 to enhance the advantageous properties of garlic.

WO 03/068231 relates to compositions which comprise folic acid, vitamin B6 and vitamin B12, and to the use thereof for regulating homocysteine levels. The
25 quantitative ratio of folic acid to vitamin B6 and of vitamin B12 to vitamin B6 is stated to be in a range from about 1:67 to 1:150 by weight, and the quantitative ratio of folic acid to vitamin B12 is stated to be in a range from about 1:0.67 to 1:1.50 by
30 weight. These compositions have a reliable effect lowering homocysteine levels. It has, however, been found that although in certain disorders such as chronic renal failure and the dialysis treatment associated therewith, or in patients treated with
35 immunosuppressants, elevated homocysteine levels can be reduced, they often cannot be returned to a normal extent.

WO 2006/074918

PCT/EP2006/000198

- 4 -

It has now been found that the combined use of folic acid, vitamin B6 and vitamin B12 in particular quantities surprisingly reduces the homocysteine level in certain cases even more effectively and thus the risk of vascular disorders in particular in certain patient groups can be reduced even further than with the previously disclosed combinations of folic acid, vitamin B6 and vitamin B12.

10 The present invention therefore relates to compositions based on folic acid, vitamin B6 and vitamin B12 or physiologically acceptable derivatives and/or salts thereof, characterized in that the quantitative ratios of folic acid to vitamin B6 is in a range from about 15 1:5 to about 1:15, the quantitative ratio of vitamin B12 to vitamin B6 is in a range from about 1:50 to about 1:125, and the quantitative ratio of folic acid to vitamin B12 is in a range from about 1:0.05 to about 1:0.25.

20

The inventive compositions based on folic acid, physiologically acceptable derivatives or salts thereof (also referred to for simplicity as "folic acids" or "folic acid component"), vitamin B6, physiologically acceptable derivatives or salts thereof (also referred to for simplicity as "B6 vitamins" or "vitamin B6 component") and vitamin B12, physiologically acceptable derivatives or salts thereof (also referred to for simplicity as "B12 vitamins" or "vitamin B12 component") offer considerable advantages in regulating homocysteine levels and thus in the preventive and acute treatment of vascular disorders.

35 The present invention therefore also relates to the use of the inventive combination of folic acid, vitamin B6 and vitamin B12 or physiologically acceptable derivatives and/or salts thereof for regulating the homocysteine level. The regulation relates in

WO 2006/074918

PCT/EP2006/000198

- 5 -

particular in the acute sphere to the reduction of elevated homocysteine levels, i.e. in particular the treatment of hyperhomocysteinemia, and in the prophylactic sphere to the prevention of elevated
5 homocysteine levels and the maintenance of normal homocysteine levels. The regulation of homocysteine levels is associated in particular with a prophylactic treatment of disorders connected with elevated homocysteine levels, i.e. especially those accompanied
10 or caused by elevated homocysteine levels.

The present invention therefore further relates to the use of the inventive combination of folic acid, vitamin B6 and vitamin B12 or physiologically acceptable
15 derivatives and/or salts thereof for treating disorders which are connected with an elevated homocysteine level. These include in particular vascular disorders such as arteriosclerosis, venous thromboses and arterial occlusions, fetal damage such as neural tube
20 defects, and neurodegenerative disorders such as certain types of Alzheimer's dementia.

In this sense, the invention also relates to compositions for regulating the homocysteine level and
25 for treating disorders which are connected with elevated homocysteine levels. These compositions are based on the inventive active ingredient combination and, where appropriate, further active ingredients, it being preferable for the active ingredients or active
30 ingredient components to be formulated together in one formulation or separately in at least two or three different formulations.

Particular advantages of use of the active ingredient
35 combination of the invention emerge in certain patient groups in which although the homocysteine levels are reduced, they are not normalized, with known compositions. These include in particular individuals

WO 2006/074918

PCT/EP2006/000198

- 6 -

with renal failure and those treated with immunosuppressants.

Preferred compositions and uses are those in which the
5 quantitative ratio of folic acid to vitamin B6 is in a
range from about 1:6 to about 1:14.5, the quantitative
ratio of vitamin B12 to vitamin B6 is in a range from
about 1:52.5 to about 1:116, and the quantitative ratio
of folic acid to vitamin B12 is in a range from about
10 1:0.07 to about 1:0.20.

Advantageous compositions and uses are those in which
the quantitative ratio of folic acid to vitamin B6 is
in a range from about 1:6 to about 1:12, the
15 quantitative ratio of vitamin B12 to vitamin B6 is in a
range from about 1:53 to about 1:97, and the
quantitative ratio of folic acid to vitamin B12 is in a
range from about 1:0.09 to about 1:0.16.

20 Particularly advantageous compositions and uses are
those in which the quantitative ratio of folic acid to
vitamin B6 is in a range from about 1:6 to about 1:10,
the quantitative ratio of vitamin B12 to vitamin B6 is
in a range from about 1:53 to about 1:83, and the
25 quantitative ratio of folic acid to vitamin B12 is in a
range from about 1:0.11 to about 1:0.14.

In this connection, the stated quantitative ratios
relate to quantities by weight of the active
30 ingredients folic acid, vitamin B6 and vitamin B12, so
that an appropriate conversion must take place where
necessary for salts and derivatives. This applies
analogously to the active ingredient contents indicated
in the present description. Alternatively, the ratios
35 can also be based on molar quantities, so that on the
assumption that one mole of the relevant derivative or
salt comprises one mole of folic acid, vitamin B6 or
vitamin B12, the molar quantitative ratios for folic


WO 2006/074918

PCT/EP2006/000198


- 7 -

acid, vitamin B6, vitamin B12 and their derivatives and/or salts can be expressed uniformly.

"Folic acid" refers according to the invention to N-
5 pteroylglutamic acid of the formula I



including the optical isomers covered by this formula,
10 both as mixtures, e.g. as racemate, and in pure form,
e.g. R or S enantiomers. N-Pteroyl-L-glutamic acid of
the formula Ia




15

is preferred. The folic acid derivatives include in particular folic acid metabolites, amides and esters of folic acid, as well as the metabolites. Amides and esters which can be hydrolyzed under physiological
20 conditions, such as amides with C₁-C₁₀-alkylamines or esters with C₁-C₁₀-alcohols are advantageous. A particular form of the amides are N-pteroylpolyglutamic acids.

25 The folic acid metabolites include in particular H₄-folic acids of the formula Ib

- 8 -



in which R1 is hydrogen, methyl, -HC=O (formyl) or -HC=NH (formimino), and R2 is hydrogen or -HC=O (formyl), or R1 and R2 together form a methylene or methenyl bridge. The optical isomers covered by this formula are included in accordance with the above statements, with preference for the L-glutamic acid derivatives in this case too. Particular mention should be made of tetrahydrofolic acid, 5-methyltetrahydrofolic acid, 5,10-methylenetetrahydrofolic acid, 5-formyltetrahydrofolic acid, 10-formyltetrahydrofolic acid, 5-formiminotetrahydrofolic acid and 5,10-methenyltetrahydrofolic acid.

15

The physiologically acceptable salts of folic acid and folic acid derivatives include acid and base addition salts and appropriate mixed forms.

20 The acid addition salts include salts of folic acid or folic acid derivatives with inorganic acids such as hydrochloric acid, sulfuric acid, nitric acid or phosphoric acid, or organic acids, in particular carboxylic acids, e.g. acetic acid, tartaric acid, 25 lactic acid, citric acid, malic acid, mandelic acid, ascorbic acid, maleic acid, fumaric acid, gluconic acid or sulfonic acids, e.g. methanesulfonic acid, benzenesulfonic acid and toluenesulfonic acid, and the like.

30

The base addition salts include salts of folic acid or folic acid derivatives with inorganic bases, for

WO 2006/074918

PCT/EP2006/000198


- 9 -

example metal hydroxides or carbonates of alkali metals, alkaline earth metals or transition metals, or with organic bases, for example ammonia or basic amino acids such as arginine and lysine, amines, e.g. methylamine, dimethylamine, trimethylamine, triethylamine, ethylamine, diethylamine, ethylenediamine, ethanolamine, diethanolamine, 1-amino-2-propanol, 3-amino-1-propanol or hexamethylenetetramine, saturated cyclic amines having 4 to 6 ring carbon atoms, such as piperidine, piperazine, pyrrolidine and morpholine, and further organic bases, for example N-methylglucamine, creatine and tromethamine, and quaternary ammonium compounds such as tetramethylammonium and the like.

15

Salts with inorganic bases are preferred, e.g. Na, K, Mg, Ca, Zn, Cr and Fe folates.

"Vitamin B6" designates according to the invention 4,5-bis(hydroxymethyl)-2-methyl-3-pyridinol of the formula II



II

25 also referred to as pyridoxine (INN).

The vitamin B6 derivatives include in particular pyridoxals and pyridoxamines, and esters of pyridoxines, pyridoxals and pyridoxamines. Also advantageous in this case are esters which can be hydrolyzed under physiological conditions.


30

WO 2006/074918

PCT/EP2006/000198

- 10 -

Particular mention should be made in this connection of the pyridoxines, pyridoxals and pyridoxamines of the formula IIa



IIa

5

in which R_3 is CH_2OH , CHO or CH_2NH_2 , and R^4 is OH or OPO_3H_2 .

10 Physiologically acceptable salts of vitamin B6 or vitamin B6 derivatives include in particular acid addition salts, e.g. with the abovementioned inorganic and organic acids. Particular mention should be made of the hydrochloride, especially pyridoxine HCl.

15

"Vitamin B12" is also referred to as cyanocobalamin or cobalamin.

20 Vitamin B12 derivatives include in particular cobalamins in which the cyano group of the cyanocobalamin is replaced by other cobalt coordination partners. These include in particular hydroxocobalamin, aquocobalamin, nitrosocobalamin, methylcobalamin and adenosylcobalamin (coenzyme B12).

25

Physiologically acceptable salts of vitamin B12 or vitamin B12 derivatives include in particular acid addition salts, e.g. with the abovementioned inorganic and organic acids. The acetate of hydroxocobalamin
30 should be mentioned in particular.

Folic acids, B6 and B12 vitamins are sufficiently well known and can be either purchased or made available in a manner known per se.

WO 2006/074918

PCT/EP2006/000198

- 11 -

Besides the folic acid, vitamin B6 and vitamin B12 components, the inventive compositions may include further active ingredients. These active ingredients
5 may be in particular those whose effect is similar to the effect mediated by folic acid, vitamin B6 and vitamin B12 or supplements the latter and which in particular complies with the inventive purposes of use. Thus, in addition to the inventive combination, it may
10 be advantageous to administer active ingredients which lower the homocysteine level, antithrombotics, antisclerotics and the like.

Assays for determining homocysteine levels, which are
15 normally in the range from 5 to 15 $\mu\text{mol/l}$ of blood plasma, are known (cf. for example the prior art described at the outset). Elevated homocysteine levels are referred to as hyperhomocysteinemia. Elevated homocysteine levels can be reduced or preventively
20 averted with the aid of the inventive compositions.

Depending on the homocysteine level, hyperhomocysteinemias are divided into three classes:

25 Mild hyperhomocysteinemias are characterized by homocysteine levels in a range from more than 15 and up to 30 $\mu\text{mol/l}$ of blood plasma.

Moderate hyperhomocysteinemias are characterized by
30 homocysteine levels in the range from more than 30 and up to 100 $\mu\text{mol/l}$ of blood plasma.

High hyperhomocysteinemias are characterized by homocysteine levels of more than 100 $\mu\text{mol/l}$ of blood
35 plasma.

WO 2006/074918

PCT/EP2006/000198

- 12 -

Particular advantages emerge according to the invention in relation to the treatment of moderate hyperhomocysteinemias.

- 5 The present invention is directed in particular to the treatment of one or more of the following pathological states:

Hereditary hyperhomocysteinemia. The pathological state
10 of hereditary hyperhomocysteinemia is characterized by genetically related disturbances of homocysteine metabolism. Metabolic disturbances of this type include in particular an absence (homozygous form) or deficiency (heterozygous form) of cystathionine β -
15 synthase, a deficiency of methylenetetrahydrofolate reductase, a mutation-related modification of methylenetetrahydrofolate reductase into a thermolabile derivative thereof, and a number of other alterations in folic acid, vitamin B6, vitamin B12 and betaine
20 metabolism. The signs and symptoms of hereditary hyperhomocysteinemia include homocysteinuria, mental retardation, dislocation of the lens of the eye, skeletal abnormalities and/or vascular disorders, which can thus be treated acutely or preventively according
25 to the invention as symptom or syndrome.

Acquired hyperhomocysteinemia. Acquired types of hyperhomocysteinemia are usually characterized by manifestations of deficiency which lead to accumulation
30 of homocysteine. For example, deficiencies of folic acid and folic acid derivatives, vitamin B12 and vitamin B12 derivatives, vitamin B6 and vitamin B6 derivatives, and a general vitamin deficiency, may lead to elevated homocysteine levels. It is moreover
35 possible for the vitamin deficiency to be caused for example by an inadequate intake or by malabsorption of the respective vitamin(s). Elevated homocysteine levels may also be caused by medicaments able to influence

WO 2006/074918

PCT/EP2006/000198

- 13 -

follic acid metabolism, such as methotrexate or anticonvulsants; able to influence vitamin B12 metabolism, such as nitrates; or able to influence vitamin B6 metabolism, such as theophylline. In addition, the homocysteine plasma level is influenced by age, gender, cigarette smoking, essential hypertension, hypercholesterolemia and insufficient exercise.

10 The present invention is additionally directed at the treatment of disorders which are connected with elevated homocysteine levels, in particular are associated therewith or caused thereby. These include in particular vascular disorders, fetal malformations
15 and certain neurodegenerative disorders. Prevention is particularly important in this area of indications.

Vascular disorders means disorders of the peripheral, coronary and cerebral vessels. Particular mention
20 should be made of alterations in vascular endothelial cells, proliferation of muscle cells and/or thickening of the intima of vessels. It is thus possible to treat according to the invention in particular arterio-scleroses, venous thromboses, arterial occlusions and
25 further arteriovenous vascular disorders.

Fetal malformations, especially neural tube defects, may occur if the mother suffers from elevated homocysteine levels during pregnancy.

30

Elevated homocysteine levels may also be involved in neurodegenerative disorders, especially vascular forms of dementia in the elderly.

35 The invention is thus directed according to a particular aspect at reducing the risk of the occurrence of the vascular disorders, fetal

WO 2006/074918

PCT/EP2006/000198

- 14 -

malformations and neurodegenerative disorders described above.

Particular advantages of a use of the active ingredient combination of the invention emerge in certain patient groups in which although the homocysteine levels are reduced, they are not normalized, with known compositions.

10 These include in particular individuals with renal failure. Renal failure means according to the invention that the elimination efficiency of the kidney is inadequate or absent. These include individuals with a creatinine clearance CL_{CR} of less than 100 ml/min, especially less than 50 ml/min and in particular less than 10 ml/min. The use of the active ingredient combination of the invention is directed in particular at the treatment of individuals with chronic renal failure. These are individuals whose renal elimination efficiency is permanently inadequate or absent. In this case, regular hemodialysis is required. The use according to the invention is very particularly preferred for individuals with advanced chronic renal failure (also referred to as terminal renal failure TRF; also: end stage renal disease ESRD) and accordingly on average with hemodialysis at least twice and in particular about three times a week.

The patient groups which can be treated advantageously include those which will undergo, are undergoing or have undergone an immunosuppressant therapy. Individuals treated with immunosuppressants are for example those suffering from an autoimmune disease or an immunoproliferative disorder, or have received a transplant. Autoimmune diseases include for example lupus (lupus erythematosus, lupus nephritis), Hashimoto's thyroiditis, primary myxedemas, Basedow's disease, pernicious anemia, autoimmune atrophic

WO 2006/074918

PCT/EP2006/000198

- 15 -

gastritis, Addison's disease, diabetes (e.g. insulin-dependent diabetes mellitus, type I diabetes mellitus), Goodpasture's syndrome, myasthenia gravis, pemphigus, Crohn's disease, sympathetic ophthalmia, autoimmune
5 uveitis, multiple sclerosis, autoimmune hemolytic anemia, idiopathic thrombocytopenia, primary biliary cirrhosis, chronic hepatitis, ulcerative colitis, Sjögren's syndrome, rheumatic disorders (e.g. rheumatoid arthritis), polymyositis, scleroderma and
10 mixed connective tissue disorders. Immunoproliferative disorders include for example psoriasis, T-cell lymphomas, acute lymphoblastic T-cell leukemia, testicular angiocentric T-cell lymphomas and benign lymphocytic angiitis. Transplant-related disorders
15 include graft versus host disease (GVHD) (e.g. as a consequence of a bone marrow transplantation or of a tolerance induction), disorders associated with acute and/or chronic rejection of one of tissue or cell transplants, allografts or xenografts.

20

The therapeutic immunosuppressants normally administered include calcineurin inhibitors such as cyclosporin and FK506, alkylating active ingredients such as cyclophosphamide, DHFA reductase inhibitors
25 such as methotrexate, azathioprine, chloroquine, hydroxychloroquine, sulphasalazine, leflunomide, gold salts, penicillamine, cytokine blockers, e.g. IL-1 antagonists such as anakinra and AMG719, TNF α antagonists such as infliximab, etanercept and humira,
30 TNF receptor antagonists such as pegsunercept, LFA-1 antagonists such as efalizumab, steroids, e.g. corticosteroids and in particular glucocorticoids such as prednisone, NSAIDs such as acetylsalicylic acid, choline magnesium salicylate, diflunisal, magnesium
35 salicylate, salsalate, sodium salicylate, diclofenac, etodolac, fenoprofen, flurbiprofen, indomethacin, ketoprofen, ketorolac, meclofenamate, naproxen, nabumetone, phenylbutazone, piroxicam, sulindac,

WO 2006/074918

PCT/EP2006/000198

- 16 -

tolmetin, acetaminophen, ibuprofen, meloxicam, codeine phosphate, propoxyphene napsylate, oxycodone hydrochloride, oxycodone bitartrate and tramadol, a large number of proteins directed against surface
5 proteins of lymphocytes, such as antibodies and fusion proteins, VLA4 antagonists, selectin antagonists, rapamycin 40-O-(2-hydroxy)ethylrapamycin, mizoribine, mycophenolic acid, mycophenolate mufetil, 15-deoxyspergualine, tacrolimus, basiliximab, Cytosan, interferon-
10 β -1a, interferon- β -1b, glatiramer acetate and mitoxantrone hydrochloride.

The inventive compositions and uses become increasingly important in adults with increasing age. The treatment
15 has particular advantages in the group of over 40s and especially the over 50s. The inventive treatment is indicated in particular when there is evidence of arterioscleroses, arterial occlusions, venous thromboses and/or vascular forms of dementia in the
20 elderly, or there is a risk of these disorders. A further group in which the inventive treatment may have particular advantages are children with hereditary hyperhomocysteinemia, and pregnant women, even if there is no evidence of vascular disorders and the
25 homocysteine levels are only slightly elevated.

According to the invention, the individual to be treated, preferably a mammal, especially a human and also a productive or domestic animal, receives
30 administration of an effective amount of the inventive active ingredient combination of folic acid component, vitamin B6 component and vitamin B12 component, usually formulated in accordance with pharmaceutical, veterinary or food technological practice. An amount is
35 effective according to the invention especially when it brings about a significant reduction in the homocysteine level, advantageously into the normal range.

- 17 -

The treatment usually takes place by single or multiple daily administration of a single dose, where appropriate together or alternately with other active ingredients or active ingredient-containing products, so that an individual to be treated with the weight of an average adult of about 75 kg usually receives administration of a minimum daily dose of about 4 mg, preferably about 5 mg and advantageously about 6 mg, of folic acid; of about 42 mg, e.g. of about 45 mg or of about 50 mg, of vitamin B6; and of about 0.5 mg, preferably about 0.6 mg and advantageously about 0.7 mg, of vitamin B12. According to another aspect, the maximum daily dose is usually about 7 mg, e.g. about 6.5 mg or about 6 mg, of folic acid; about 58 mg, e.g. about 55 mg or about 50 mg, of vitamin B6; and about 0.8 mg, e.g. 0.75 mg or about 0.7 mg, of vitamin B12. Accordingly, the maximum daily doses are in the range of 4 to 7 mg, preferably 5 to 7 mg and in particular 6 to 7 mg of folic acid; 42 to 58 mg of vitamin B6; and 0.5 to 0.8 mg, preferably 0.6 to 0.8 mg and in particular 0.7 to 0.8 mg of vitamin B12. The daily dose should be adjusted appropriately if the weight differs from the average. This adjustment takes place in a conventional way by the skilled worker, if necessary taking account of analytical investigations. In addition, differences in the daily dose prescribed by the physician may also arise owing to the state of health of the individual to be treated.

30

The treatment usually takes place over an appropriate period in the region of days or weeks. It is expedient to normalize the homocysteine levels within a treatment period of about 1 to 4 weeks. If necessary, the treatment is also continued after the homocysteine levels have normalized. This applies in particular to the hereditary types of hyperhomocysteinemia and acquired types in which a causative treatment is not

WO 2006/074918

PCT/EP2006/000198

- 18 -

possible or has no success, and discontinuation of the inventive treatment would result in a renewed rise in the homocysteine levels.

- 5 The invention also relates to the production of compositions for the treatment of an individual, preferably a mammal, in particular a human and also a productive or domestic animal.
- 10 The compositions include in particular pharmaceutical compositions, food supplements and food products, e.g. functional or dietetic food products. The inventive food products have, besides a function predominantly related to nutritional value, additionally a function
- 15 related to the active ingredients and particularly related to the inventive active ingredient combination. They are therefore referred to as functional or dietetic food or nutritional products. Food supplements serve to supplement the daily diet with the inventive
- 20 active ingredient combination, in which case the function related to the nutritional value of the food supplement becomes less important as such.

According to one aspect, the present invention relates

25 to formulations comprising

- i) at least one active ingredient from the folic acid group (folic acid, physiologically acceptable derivatives and/or salts thereof),
 - ii) at least one active ingredient from the vitamin B6
 - 30 group (vitamin B6, physiologically acceptable derivatives and/or salts thereof), and
 - iii) at least one active ingredient from the vitamin B12 group (vitamin B12, physiologically acceptable derivatives and/or salts thereof), and
- 35 where appropriate at least one further active ingredient and a formulation base, in the quantitative ratios indicated according to the invention.

WO 2006/074918

PCT/EP2006/000198

- 19 -

Thus, the active ingredient combination comprises for the purposes of the invention as active ingredient component i) folic acid, a physiologically acceptable derivative and/or salt thereof. Mixtures of these forms
5 are possible but are to be considered only in particular cases. According to a particular embodiment, active ingredient component i) consists of at least 90% by weight folic acid.

10 The active ingredient combination additionally comprises for the purposes of the invention as active ingredient component ii) vitamin B6, a physiologically acceptable derivative and/or salt thereof. Mixtures of these forms are likewise possible, but are to be
15 considered only in particular cases. According to a particular embodiment, active ingredient component ii) consists of at least 90% by weight pyridoxine HCl.

The active ingredient combination additionally
20 comprises for the purposes of the invention as active ingredient component iii) vitamin B12, a physiologically acceptable derivative and/or salt thereof. Mixtures of these forms are likewise possible, but are to be considered only in particular cases.
25 According to a particular embodiment, active ingredient component iii) consists of at least 90% by weight cobalamin.

The content of the active ingredient combination in the
30 formulation is larger than the content present where appropriate in natural sources, in particular food products. In this sense, the inventive compositions are fortified in relation to the active ingredient combination. The content of active ingredient
35 combination of i), ii) and iii) in the formulation is preferably at least about 0.01% by weight, advantageously at least about 0.05% by weight and in particular at least about 0.1% by weight. In the case

WO 2006/074918

PCT/EP2006/000198

- 20 -

of a pharmaceutical composition, the content is usually about 1 to 60% by weight, preferably about 5 to 35% by weight, and in particular about 10 to 30% by weight, and in the case of a food supplement and especially in
5 the case of food products where appropriate correspondingly lower if the formulation is given in larger amounts. The formulations preferably comprise the indicated daily dose.

10 Unless otherwise indicated, data in % by weight are based on the total weight of the formulation.

The formulation base for novel formulations comprises physiologically acceptable excipients. Physiologically
15 acceptable excipients are those known to be usable in the sectors of pharmacy, food technology and adjacent areas, in particular the excipients listed in relevant pharmacopeias (e.g. DAB, Ph. Eur., BP, NF), and other excipients whose properties do not stand in the way of
20 physiological use. Excipients for the purposes of the invention may also have a nutritional value and are therefore generally used as food component. They may also include nutrients, especially essential nutrients.

25 Suitable excipients may be: wetting agents; emulsifying and suspending agents; preservatives; antioxidants; antiirritants; chelating agents; tablet coating aids; emulsion stabilizers; film formers; gel formers; odor-
masking agents; masking flavors; resins; hydrocolloids;
30 solvents; solubilizers; neutralizers; permeation promoters; pigments; quaternary ammonium compounds; refatting and superfatting agents; ointment, cream or oil bases; silicone derivatives; spreading aids; stabilizers; sterilants; suppository bases; tablet
35 excipients such as binders, fillers, lubricants, disintegrants or coatings; propellants; desiccants; opacifiers; thickeners; waxes; plasticizers; white oils. An arrangement concerning this is based on

- 21 -

specialist knowledge as described, for example, in Fiedler, H.P., Lexikon der Hilfsstoffe für Pharmazie, Kosmetik und angrenzende Gebiete, 4th edition, Aulendorf: ECV-Editio-Cantor-Verlag, 1996.

5

Food components usually comprise one or more amino acids, carbohydrates or fats and are suitable for the human and/or animal diet. They comprise individual components, frequently vegetable but also animal products, especially sugars, where appropriate in the form of syrups, fruit preparations such as fruit juices, nectar, fruit pulps, purées or dried fruit, for example apple juice, grapefruit juice, orange juice, apple purée, tomato sauce, tomato juice, tomato purée; cereal products such as wheat flour, rye flour, oat flour, corn flour, barley flour, spelt flour, corn syrup and starches from said cereals; dairy products such as milk protein, whey, yoghurt, lecithin and lactose.

20

Essential nutrients include, in particular, vitamins, provitamins, trace elements, amino acids and fatty acids. Essential amino acids which may be mentioned are isoleucine, leucine, lysine, methionine, phenylalanine, threonine, tryptophan and valine. They also include semiessential amino acids which must be given, for example, in periods of growth or deficiency states, such as arginine, histidine, cysteine and tyrosine. Trace elements which may be mentioned are: essential trace elements which have been proved to be necessary for humans and deficiency of which leads to manifestation of signs and symptoms: iron, copper, zinc, chromium, selenium, calcium, magnesium, potassium, lithium, cobalt, molybdenum, iodine, silicon, fluorine, manganese. Likewise elements whose function in humans is as yet inadequately verified: tin, nickel, vanadium, arsenic, manganese. Fatty acids essential for humans which may be mentioned are:

WO 2006/074918

PCT/EP2006/000198

- 22 -

linoleic acid and linolenic acid. A comprehensive list of vitamins is to be found in "Referenzwerte für die Nährstoffzufuhr", 1st edition, Umschau Braus Verlag, Frankfurt am Main, 2000, edited by the Deutsche
5 Gesellschaft für Ernährung.

The total of active ingredient component and formulation base is usually 100% by weight.

- 10 Examples of suitable formulations for food supplementation are capsules, tablets, pills, powder sachets, liquid ampoules and bottles with stopper inserts, besides the drug forms mentioned below.
- 15 Examples of suitable pharmaceutical formulations are solid drug forms such as oral powders, dusting powders, granules, tablets, especially film-coated tablets, pastilles, sachets, cachets, sugar-coated tablets, capsules such as hard and soft gelatin capsules,
- 20 suppositories or vaginal drug forms, semisolid drug forms such as ointments, creams, hydrogels, pastes or patches, and liquid drug forms such as solutions, emulsions, especially oil-in-water emulsions, suspensions, for example lotions, preparations for
- 25 injection and infusion, eye drops and ear drops. It is also possible to use implanted delivery devices for administering active ingredients of the invention. Liposomes or microspheres may also be used.
- 30 Food formulations usually have the customary form and are preferably made available in the form of infant food, breakfast products, especially in the form of mueslis or bars, sports beverages, complete meals, especially in the framework of complete balanced diets,
- 35 dietetic products such as diet drinks, diet meals and diet bars.

WO 2006/074918

PCT/EP2006/000198

- 23 -

The formulations are preferably administered by the oral route, but they can also be administered, especially in the pharmaceutical sector, by the rectal, transdermal, subcutaneous, intravenous, intramuscular or intranasal route.

For producing the compositions, the active ingredients are usually mixed or diluted with a suitable excipient. Excipients may be solid, semisolid or liquid materials serving as vehicle, carrier or medium for the active ingredient. Admixture of other excipients takes place, if necessary, in a manner known per se. It is possible to carry out shaping steps, where appropriate in conjunction with mixing processes, e.g. a granulation, compression and the like.

The active ingredient components can in particular be formulated together. However, they also be initially processed separately and subsequently combined in a compartmented, e.g. multilayer pharmaceutical form. It is thus possible to take account of possible active ingredient incompatibilities and different active ingredient properties such as bioavailability, stability, solubility and the like.

The present invention is explained in more detail by means of the following examples without being restricted thereto.

Example 1

Pharmaceutical compositions

a) Soft gelatin capsules

(folic acid 6 mg + vitamin B6 50 mg + vitamin B12 0.6 mg)

Filling:

folic acid	6	mg
vitamin B6	50	mg

WO 2006/074918

PCT/EP2006/000198

- 24 -

	vitamin B12	0.6	mg
	soybean oil (refined)	440	mg
	soybean lecithin (E322)	50	mg
	colloidal silica	5	mg
5	Capsule shell:		
	gelatin	303	mg
	glycerol 85%	87	mg
	sorbitol 70%	77	mg
	purified water	52	mg
10	iron oxide pigment brown 75 (E 172)	3	mg
	b) Tablet		
	(folic acid 5 mg + vitamin B6 45 mg + vitamin B12 0.5 mg)		
15	folic acid	5	mg
	vitamin B6	45	mg
	vitamin B12	0.5	mg
	lactose	127.5	mg
	magnesium stearate	5	mg
20	talc	23.75	mg
	microcrystalline cellulose	81	mg

Example 2

Patient with chronic renal failure

25 A 42-year old man with terminal renal failure has undergone regular hemodialysis for 6 years. The homocysteine level was 38 $\mu\text{mol/l}$. On daily oral administration of 1 mg of folic acid, 1 mg of vitamin B12 and 100 mg of vitamin B6 to this man, the

30 homocysteine level fell to 24.4 $\mu\text{mol/l}$ after 8 weeks. No further reduction occurred during the subsequent 3 months, despite continuation of the therapy. On discontinuation of the therapy, the homocysteine level again rose to 38 $\mu\text{mol/l}$ within 8 weeks.

35

On daily oral administration now of 5 mg of folic acid, 0.7 mg of vitamin B12 and 50 mg of vitamin B6, the

WO 2006/074918

PCT/EP2006/000198

- 25 -

homocysteine level fell to 12.6 $\mu\text{mol/l}$ after therapy for 8 weeks.

Example 3

5 Patient receiving cyclosporin therapy

A 36-year old patient with severe, therapy-resistant psoriasis vulgaris received 2.5 mg of cyclosporin per kg of body weight each day. The homocysteine level was 47 $\mu\text{mol/l}$.

10

On daily oral administration of 1 mg of folic acid, 1 mg of vitamin B12 and 100 mg of vitamin B6 to this man, the homocysteine level fell to 28.6 $\mu\text{mol/l}$. On discontinuation of the therapy, the homocysteine level
15 rose to 47 $\mu\text{mol/l}$ again after 4 weeks.

Subsequent therapy with daily oral administration of 6 mg of folic acid, 0.6 mg of vitamin B12 and 50 mg of vitamin B6 led to a reduction in the homocysteine level
20 to 14.2 $\mu\text{mol/l}$ after 8 weeks.

On discontinuation of this therapy, the homocysteine level again rose to 47 $\mu\text{mol/l}$ after 8 weeks.


25 Subsequent therapy with daily oral administration of 5 mg of folic acid, 0.8 mg of vitamin B12 and 50 mg of vitamin B6 led to a renewed fall in the homocysteine level to 14.2 $\mu\text{mol/l}$ after 8 weeks.

30

Claims


1. A composition based on folic acid, vitamin B6 and vitamin B12 or physiologically acceptable derivatives and/or salts thereof, characterized in that the quantitative folic acid: vitamin B6 ratio is in a range of 1:5-15 by weight, the quantitative vitamin B12: vitamin B6 ratio is in a range of 1:50-125 by weight, and the quantitative folic acid: vitamin B12 ratio is in a range of 1:0.05-0.25 by weight,

wherein the physiologically acceptable folic acid derivatives are selected from among folic acid metabolites of formula Ib



wherein R1 denotes hydrogen, methyl, $-HC=O$ or $-HC=NH$ and R2 denotes hydrogen or $-HC=O$, or R1 and R2 taken together form a methylene or methenyl bridge, and esters and amides of folic acid and the folic acid metabolites,

the physiologically acceptable vitamin B6 derivatives are selected from among pyridoxines, pyridoxals and pyridoxamines of formula IIa



wherein R3 denotes CH_2OH , CHO or CH_2NH_2 and R4 denotes OH or OPO_3H_2 and esters of the pyridoxines, pyridoxals and pyridoxamines and

the physiologically acceptable vitamin B12 derivatives are selected from among cobalamins, wherein the cyano group of the cyanocobalamin is replaced by other coordination partners of cobalt.

2. The composition as claimed in claim 1, characterized in that the quantitative folic acid:vitamin B6 ratio is in a range of 1:6-14.5 by weight, the quantitative vitamin B12:vitamin B6 ratio is in a range of 1:52.5-116 by weight, and the quantitative folic acid:vitamin B12 ratio is in a range of 1:0.07-0.20 by weight.
3. The composition as claimed in claim 1, characterized in that the quantitative folic acid:vitamin B6 ratio is in a range of 1:6-10 by weight, the quantitative vitamin B12:vitamin B6 ratio is in a range of 1:53-83 by weight, and the quantitative folic acid:vitamin B12 ratio is in a range of 1:0.11-0.14 by weight.
4. The use of folic acid, vitamin B6 and vitamin B12 or physiologically acceptable derivatives and/or salts thereof as defined in claim 1, for producing a composition for regulating homocysteine levels, characterized in that the quantitative folic acid:vitamin B6 ratio is in a range of 1:5-15 by weight, the quantitative vitamin B12:vitamin B6 ratio is in a range of 1:50-125 by weight, and the quantitative folic acid:vitamin B12 ratio is in a range of 1:0.05-0.25 by weight.
5. The use as claimed in claim 4, where the homocysteine levels which are to be regulated occur in an individual with renal failure or treated with immunosuppressants.
6. The use of folic acid, vitamin B6 and vitamin B12 or physiologically acceptable derivatives and/or salts thereof as defined in claim 1, for producing a composition for treating vascular disorders, characterized in that the quantitative folic acid:vitamin B6 ratio is in a range of 1:5-15 by weight, the quantitative vitamin B12:vitamin B6 ratio is in a range of 1:50-125 by weight, and the quantitative folic acid:vitamin B12 ratio is in a range of 1:0.05-0.25 by weight.

7. The use as claimed in claim 6, where the vascular disorder affects an individual with renal failure or treated with immunosuppressants.
8. The use as claimed in claim 6 or 7, where the vascular disorder is an arteriosclerosis, an arterial occlusion, a venous thrombosis or a vascular form of dementia in the elderly.
9. The use as claimed in any one of claims 4 to 8, where the daily dose is from 4 mg to 7 mg of folic acid, from 42 mg to 58 mg of vitamin B6 and from 0.5 mg to 0.8 mg of vitamin B12.
10. The use as claimed in any one of claims 4 to 8, where the daily dose is from 6 mg to 7 mg of folic acid, from 42 mg to 58 mg of vitamin B6 and from 0.7 mg to 0.8 mg of vitamin B12.